Stem Cell Vesicles Block Post-Heart Attack Scarring and Prevent Heart Failure
A GMP-compatible extracellular vesicle therapy from bone marrow stem cells prevents cardiac fibrosis and preserves heart function after heart attack.
Summary
After a heart attack, the scarring process (fibrosis) that follows can silently destroy heart function over weeks. Researchers at Uppsala University developed a therapy using tiny biological particles — extracellular vesicles — secreted by bone marrow stem cells. Grown under conditions suitable for clinical manufacturing, these vesicles reduced scar-forming cell activation, promoted healing immune responses, and preserved heart pumping function in both mouse and pig models of heart attack. The team also created a specialized PET imaging tool targeting a fibrosis marker (PDGFRβ) to track scar activity in actual heart attack patients, finding that myofibroblast activation can persist for up to two months. This combined treatment-plus-imaging approach opens a path toward personalized, fibrosis-targeted therapy after heart attack.
Detailed Summary
Heart failure following a heart attack remains one of the leading causes of death and disability worldwide. After the initial blockage and reperfusion injury, the heart undergoes adverse remodeling — primarily driven by fibrosis, or scarring — that progressively weakens pumping function. As the authors note, no therapy directly targets this fibrotic response, leaving a major unmet clinical need.
Researchers developed an extracellular vesicle (EV)-enriched secretome derived from bone marrow mesenchymal stromal cells, produced using a laminin-521 substrate compatible with good manufacturing practice (GMP) standards required for clinical translation. These nanoscale biological particles carry proteins, lipids, and RNA signals that modulate recipient cells without the risks associated with whole-cell therapies.
In mouse models of myocardial ischemia-reperfusion injury, EV treatment preserved left ventricular ejection fraction, reduced activation of scar-forming myofibroblasts (measured via PDGFRβ-targeted PET imaging), attenuated overall fibrosis, and shifted macrophage polarization toward a reparative, anti-inflammatory phenotype. Critically, cardioprotective effects were also confirmed in a porcine ischemia-reperfusion model — a much closer physiological analog to human cardiac anatomy — with intracoronary administration, the same delivery route used in current cardiac catheterization procedures.
The team simultaneously developed a PDGFRβ-targeted PET imaging platform (described in the abstract as 'clinically approved,' though details of the regulatory pathway are not provided) to non-invasively monitor fibrotic activity in STEMI patients. Preliminary findings suggest myofibroblast activation persists for up to two months post-STEMI in selected patients, highlighting a therapeutic window longer than previously appreciated.
Together, this work establishes a therapeutic-diagnostic framework that pairs an EV-based anti-fibrotic therapy with precision imaging to guide individualized treatment. Caveats include the preliminary nature of human imaging data, the abstract-only availability limiting full methodological appraisal, and unresolved questions around optimal dosing, timing, and long-term safety in humans.
Key Findings
- GMP-compatible extracellular vesicles from bone marrow stromal cells preserved heart ejection fraction in mouse heart attack models.
- EV treatment reduced myofibroblast activation and cardiac fibrosis while promoting reparative macrophage polarization.
- Intracoronary EV delivery was cardioprotective in a porcine ischemia-reperfusion model, closely mimicking clinical practice.
- A PDGFRβ-targeted PET imaging tool tracked fibrosis activity in STEMI patients, revealing myofibroblast activation up to 2 months post-event.
- The laminin-521 production platform supports clinical-grade manufacturing, accelerating potential translation to human trials.
Methodology
The study used murine and porcine myocardial ischemia-reperfusion injury models to test EV-enriched secretome therapy, with PDGFRβ-targeted PET imaging quantifying myofibroblast activation. Preliminary PDGFRβ PET imaging was also performed in human STEMI patients to assess fibrotic activity longitudinally.
Study Limitations
The human data are preliminary observations from a small number of STEMI patients, limiting definitive conclusions about the imaging platform's clinical utility. The full methodology, sample sizes, and statistical details are unavailable as only the abstract was accessible. Conflict-of-interest disclosures indicate several authors hold equity or patents related to EV technologies, which warrants independent replication.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: